Parkinson’s Disease Therapeutics Market Development Discussed by GBI Research in Topical Study Available at MarketPublishers.com
16 Jan 2015 • by Natalie Aster
LONDON – Nowadays, there are around 320 new Parkinson’s disease (PD) therapies, which are under development. The PD pipeline’s mechanism of action (MoA) differs a lot from the MoA currently employed in the market. While presently the market provides therapies targeted at neuromodulatory receptors, the pipeline includes a wide spectrum of neuroprotective therapies, that target various dysfunctional disease processes. This variety is partially owing to the existence of 90 first-in-class drugs, together accounting for 37% of the total pipeline products that revealed their target.
The market landscape now favors the first-in-class innovations, through faster approval and higher revenues, than non-first-in-class developments. This finding has certain implications for small and large PD market players. The first-in-class products entering the market can change and enhance the PD therapies landscape, despite their high attrition rate. Despite the low size of the first-in-class PD drugs market, it presents more investment opportunities, as the value of the deals is much higher if compared to deals involving non-first-in-class drugs. The first-in-class drugs, which are supported by clinical and scientific evidence, present attractive investments opportunities and have huge potential to improve the PD therapeutics market.
Topical research study “Frontier Pharma: Parkinson’s Disease - Identifying and Commercializing First-in-Class Innovation” developed by GBI Research offers an in-depth examination of the global market for PD treatments.
The in-demand research report unveils key details on the latest developments and innovations within the PD therapeutics market, analyses the top investment opportunities and mentions the latest PD drugs licensing and co-development deals within the market. In addition, the report contains an all-round and detailed description of the PD, includes an overview of its etiology, pharmacotherapy, symptoms, staging and treatment options. The first-in-class deals are thoroughly examined and are compared to non-first-in-class agreements. Besides, the comprehensive report offers an all-round assessment of the PD pipeline basing on the molecule type, development phase and therapeutic targets, reviews the pipeline programs, investigates the marketed products for PD and examines the unmet demand. Furthermore, a future outlook for the development of the world PD therapeutics market is provided.
Frontier Pharma: Parkinson’s Disease - Identifying and Commercializing First-in-Class Innovation
Published: November, 2014
Price: US$ 6,995.00
More topical market research reports by the publisher can be found at GBI Research page.